These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35638777)

  • 21. Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of
    García-Fernández S; Bala Y; Armstrong T; García-Castillo M; Burnham CA; Wallace MA; Hardy D; Zambardi G; Cantón R
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31597745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world
    Riccobene T; Ai C; Yu KC; Gregory S; Kim B; Debabov D; Gupta V
    Microbiol Spectr; 2023 Dec; 11(6):e0312923. PubMed ID: 37937985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis.
    Karakonstantis S; Rousaki M; Vassilopoulou L; Kritsotakis EI
    Clin Microbiol Infect; 2024 Feb; 30(2):178-188. PubMed ID: 37666449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-World Performance of Susceptibility Testing for Ceftolozane/Tazobactam against Non-Carbapenemase-Producing Carbapenem-Resistant Pseudomonas aeruginosa.
    Rivas L; Alcalde-Rico M; Martínez JRW; Moreno MV; Rojas P; Wozniak A; García P; Olivares-Pacheco J; Miller WR; Arias CA; Khan A; Munita JM
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0165721. PubMed ID: 34780269
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance.
    Ikenoue C; Matsui M; Inamine Y; Yoneoka D; Sugai M; Suzuki S;
    BMC Infect Dis; 2024 Feb; 24(1):209. PubMed ID: 38360618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antimicrobial susceptibilities of the ertapenem-non-susceptible non-carbapenemase-producing Enterobacterales isolates causing intra-abdominal infections in the Asia-Pacific region during 2008-2014: Results from the Study for Monitoring the Antimicrobial Resistance Trends (SMART).
    Jean SS; Hsueh PR;
    J Glob Antimicrob Resist; 2020 Jun; 21():91-98. PubMed ID: 31627023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter Clinical Evaluation of Etest Meropenem-Vaborbactam (bioMérieux) for Susceptibility Testing of
    Jean S; Garrett S; Anglade C; Bridon L; Davies L; Garner OB; Richards J; Wallace M; Wootton M; Burnham CA
    J Clin Microbiol; 2019 Dec; 58(1):. PubMed ID: 31619532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E; Cabot G; Mulet X; García-Castillo M; del Campo R; Juan C; Cantón R; Oliver A
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp.
    Mohanty S; Maurya V; Gaind R; Deb M
    J Infect Dev Ctries; 2013 Nov; 7(11):880-7. PubMed ID: 24240048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility testing of carbapenems: multicenter validity testing and accuracy levels of five antimicrobial test methods for detecting resistance in Enterobacteriaceae and Pseudomonas aeruginosa isolates.
    Steward CD; Mohammed JM; Swenson JM; Stocker SA; Williams PP; Gaynes RP; McGowan JE; Tenover FC
    J Clin Microbiol; 2003 Jan; 41(1):351-8. PubMed ID: 12517872
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
    Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Performance evaluation of VITEK 2 system in meropenem susceptibility testing of clinical Pseudomonas aeruginosa isolates].
    Acuner IC; Bayramoğlu G; Birinci A; Cekiç Cihan C; Bek Y; Durupınar B
    Mikrobiyol Bul; 2011 Jul; 45(3):411-21. PubMed ID: 21935774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Shall we report the carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii strains detected by BD Phoenix system?].
    Oğünç D; Ongüt G; Ozen NS; Baysan BO; Günseren F; Dağlar D; Demirbakan H; Gültekin M
    Mikrobiyol Bul; 2010 Apr; 44(2):197-202. PubMed ID: 20549953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS; Lee WS; Yu KW; Liao CH; Hsu CW; Chang FY; Ko WC; Chen RJ; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Lam C; Liu CY; Hsueh PR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):969-976. PubMed ID: 25661253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Implementation of a Hospital-wide Practice for the Selective Use of Carbapenems Based on the Monitoring of Susceptibility of Pseudomonas aeruginosa Isolates.
    Ohshima T; Asai S; Miyazawa M; Yamamoto Y; Hisada A; Kumazawa C; Hashimoto M; Fukawa K; Iwashita H; Umezawa K; Yamada S; Yamamoto Y; Miyachi H
    Tokai J Exp Clin Med; 2017 Dec; 42(4):176-181. PubMed ID: 29228415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
    Piérard D; Stone GG
    BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.